ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization

SIMPLE SUMMARY: NRAS-mutant melanoma is a highly aggressive subtype with few treatment options. Although both BRAF-mutant and NRAS-mutant melanomas have activation of the MEK/ERK pathway, MEK inhibitors (MEKi) are only effective for the BRAF-mutant subtype. The aim of this study was to understand wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyon, Anastasia, Tripathi, Rakshamani, Meeks, Christina, He, Daheng, Wu, Yuanyuan, Liu, Jinpeng, Wang, Chi, Chen, Jing, Zhu, Haining, Mukherjee, Sujata, Ganguly, Saptadwipa, Plattner, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913232/
https://www.ncbi.nlm.nih.gov/pubmed/36765910
http://dx.doi.org/10.3390/cancers15030954

Ejemplares similares

Ejemplares similares